Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B837-ADC
- Development stage
- Preclinical
- Lead developer
- Nanolattix
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B837-ADC is a preclinical-stage bispecific antibody-drug conjugate (BsADC) being developed by Shanxi Naan Biotechnology for the treatment of solid tumors, including colorectal cancer, lung cancer, and breast cancer. By utilizing a bispecific antibody format, B837-ADC is designed to simultaneously bind to two different tumor-associated antigens or epitopes on the surface of cancer cells. This dual-targeting approach is intended to enhance tumor selectivity, improve internalization efficiency, and potentially overcome resistance mechanisms associated with monospecific therapies. Upon binding and internalization, the ADC complex releases a cytotoxic payload to induce targeted cell death. B837-ADC is administered via intravenous injection and represents a key asset in Shanxi Naan's pipeline of next-generation antibody-based therapeutics.
- Other names
- B837-ADCB-837-ADCB 837-ADC
Beyond the preview
Go deeper on B837-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B837-ADC.